Abstract
Studies of dipeptidyl peptidase-4 inhibitors (DPP-4i) report heterogeneous effects on endothelial function in patients with type 2 diabetes. This study assessed the effects of the DPP-4i linagliptin (LINA) vs the sulfonylurea glimepiride (GLIM) and placebo (PBO) on measures of macro- and
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have